Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE-COPD-E: Metformin in COPD Exacerbations
NCT07275359Phase 1Not yet recruiting
- Sponsor
- Duke University
- Start
- Feb 2027
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in chronic obstructive pulmonary disease (COPD), sponsored by Duke University. Primary endpoints: Feasibility of metformin administration at 6 months, Acceptability of metformin administration at 6 months and 2 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07275359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275359.